Arbutus Biopharma Corporation

Protiva Biotherapeutics, Inc.

Stephen P Reid

James Heyes

Adam Judge

Ian MacLachlan

Ed Yaworski

Michael J Abrams

Lorne Ralph Palmer

Mark Wood

Edward D Yaworski

Ian Maclachlan

Kieu Mong Lam

Alan D Martin

The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.

Lipid formulations for delivery of therapeutic agents

The present invention provides compositions comprising nucleic acid molecules, such as mRNA molecules, encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease.

Compositions and methods for delivering messenger RNA

Lipid formulations for delivery of therapeutic agents to solid tumors

Lipid formulations for nucleic acid delivery

Growing community of inventors

Vancouver, Canada

Stephen P Reid